Investors can
contact
the law firm at no cost to learn more about recovering their losses
LOS ANGELES, April 08, 2022 (GLOBE NEWSWIRE) —
The Portnoy Law Firm
advises Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) investors that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Fennec securities between May 28, 2021 and November 26, 2021, inclusive (the “Class Period”).
Investors are encouraged to contact attorney
Lesley F. Portnoy
, by phone 844-767-8529 or
email
: [email protected], to discuss their legal rights, or
click here
to join the case via
www.portnoylaw.com
. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
According to the complaint filed in this lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Fennec Pharmaceuticals had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK; (2) as a result, the U.S. Food and Drug Administration was unlikely to approve the Resubmitted PEDMARK New Drug Application (“NDA”); (3) accordingly, the regulatory and commercial prospects of the Resubmitted NDA were overstated; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Please visit our
website
to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com
Attorney Advertising
